Reading CABA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CABA free→Reading CABA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CABA free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact performance compared with sector peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $3.01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.81x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.44 → $-0.34 (+21.8% / 30d). 0 raised, 0 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$284.
How much price usually moves either way.
On a bad day, this stock has moved -$765.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,349.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Good data may raise interest in Cabaletta's autoimmune products. This could improve how investors feel.
Confirms:A press release announcing positive results from the rese-cel data or trials.
Disproves:A press release about poor results from the rese-cel data or tests.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CABA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 3, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. On June 3, 2026, the Company issued the Press Release announcing new rese-cel data and development updates across the Company's autoimmune portfolio, in…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CABA Cabaletta Bio Inc | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Focus on expanding the clinical development of rese-cel in multiple indications, including ongoing myositis registrational study.
Stated in 2 of last 2 quarters. The company has consistently emphasized expanding the clinical development of rese-cel. However, financials show a net income loss of $43.5M in 2026-Q1, indicating limited progress in financial improvement. The trajectory shows recurring focus but narrow delivery so far.
“The Company intends to use proceeds to fund expanded clinical development of rese-cel.”
“Translate registrational pathways with rese-cel.”
Engage in strategic partnerships to enhance growth and development opportunities.
Stated in 2 of last 2 quarters. The company has been focusing on strategic partnerships to drive growth. Despite this, the financials show a consistent operating income loss, with $44.3M in 2026-Q1, indicating limited financial impact from these partnerships so far. The trajectory shows persistent statement but limited substantive delivery.
“The Company announced strategic partnerships to enhance growth opportunities.”
“Announced strategic partnerships to enhance growth.”
Continue efforts to manage and reduce operating expenses amidst ongoing financial challenges.
Stated in 3 of last 3 quarters. Despite efforts to manage operating expenses, the operating income loss increased from $42.6M in 2025-Q4 to $44.3M in 2026-Q1. This indicates limited progress in reducing expenses, with a trajectory showing persistent challenges.
“Operating expenses management remains a focus amidst financial challenges.”
“Efforts to manage operating expenses continue.”
“Focus on reducing operating expenses.”
Why it matters: The lawsuit's result could affect how the company works and its image.
Confirms:A press release about a good ruling or settlement in the lawsuit.
Disproves:A press release about a bad ruling or more legal issues.
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. As of March 31, 2026, the Company had approximately $117 million in cash and cash equivalents. This preliminary financial information is subject to completion, and is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not reported its financial results for the three months ended March 31, 2026, and its actual results could be materially different from this prelim…
Entry into a Material Definitive Agreement. On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The Shares are being…
Other Events. On May 14, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. On May 14, 2026, the Company issued the Press Release presenting its preconditioning-free clinical data and automated manufacturing translational data f…